Effects of CYP induction by rifampicin on tamoxifen exposure

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 62-67

  Binkhorst, L ^a   Van Gelder, T ^a   Loos, W J ^a   De Jongh, F E ^b   Hamberg, P ^c   Moghaddam Helmantel, I M Ghobadi ^a   De Jonge, E ^a   Jager, A ^a   Seynaeve, C ^a   Van Schaik, R H N ^a   Verweij, J ^a   Mathijssen, R H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; RIFAMPICIN; TAMOXIFEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; RIFAMPIN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84862626584     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.372     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Osborne, C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609-1618 (1998).
3. J in, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
4. Hoskins, J.M., Carey, L.A. & McLeod, H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9, 576-586 (2009).
5. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
6. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004).
7. Lien, E.A., Solheim, E., Lea, O.A., Lundgren, S., Kvinnsland, S. & Ueland, P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183 (1989).
8. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003).
9. Lim, Y.C., Desta, Z., Flockhart, D.A. & Skaar, T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 55, 471-478 (2005).
10. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. & Spelsberg, T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009).
11. Mürdter, T.E. et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708-717 (2011).
12. Barginear, M.F. et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin. Pharmacol. Ther. 90, 605-611 (2011).
13. Borges, S. et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006).
14. Goetz, M.P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
15. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
16. Kelly, C.M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
17. Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer. the breast international group 1-98 trial. J. Natl. Cancer Inst 104, 441-451 (2012).
18. Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl. Cancer Inst. 104, 452-460 (2012).
19. de Graan, A.J. et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol. 29, 3240-3246 (2011).
20. Madlensky, L. et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89, 718-725 (2011).
21. Gjerde, J. et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010).
22. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivisto, K.T. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003).
23. Diczfalusy, U., Nylen, H., Elander, P. & Bertilsson, L. 4beta-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br. J. Clin. Pharmacol. 71, 183-189 (2011).
24. Kivistö, K.T., Villikka, K., Nyman, L., Anttila, M. & Neuvonen, P.J. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin. Pharmacol. Ther. 64, 648-654 (1998).
25. Zheng, Y., Sun, D., Sharma, A.K., Chen, G., Amin, S. & Lazarus, P. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab. Dispos. 35, 1942-1948 (2007).
26. Iusuf, D., Teunissen, S.F., Wagenaar, E., Rosing, H., Beijnen, J.H. & Schinkel, A.H. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J. Pharmacol. Exp. Ther. 337, 710-717 (2011).
27. Teunissen, S.F. et al. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J. Pharm. Biomed. Anal. 55, 518-526 (2011).
28. Binkhorst, L. et al. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 56, 1016-1023 (2011).
29. Loos, W.J. et al. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 54, 387-394 (2011).